These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 34934197)

  • 1. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.
    Chen Y; Xu YN; Ye CY; Feng WB; Zhou QT; Yang DH; Wang MW
    Acta Pharmacol Sin; 2022 May; 43(5):1156-1166. PubMed ID: 34934197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists.
    Goldenberg RM; Gilbert JD; Manjoo P; Pedersen SD; Woo VC; Lovshin JA
    Obes Rev; 2024 Mar; 25(3):e13663. PubMed ID: 37968541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
    Patel Chavez C; Cusi K; Kadiyala S
    J Clin Endocrinol Metab; 2022 Jan; 107(1):29-38. PubMed ID: 34406410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease.
    Yabut JM; Drucker DJ
    Endocr Rev; 2023 Jan; 44(1):14-32. PubMed ID: 35907261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.
    Kayed A; Melander SA; Khan S; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2023 Mar; 384(3):406-416. PubMed ID: 36418115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease.
    Lee HA; Kim HY
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptor agonists in the treatment of diabetic non-alcoholic steatohepatitis patients.
    Adeghate EA
    Expert Opin Pharmacother; 2024 Feb; 25(3):223-232. PubMed ID: 38458647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
    Melander SA; Kayed A; Andreassen KV; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2024 Jan; 962():176215. PubMed ID: 38056618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.
    Xue H; Xing HJ; Wang B; Fu C; Zhang YS; Qiao X; Guo C; Zhang XL; Hu B; Zhao X; Deng LJ; Zhu XC; Zhang Y; Liu YF
    Drug Des Devel Ther; 2023; 17():1417-1432. PubMed ID: 37197367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological management of nonalcoholic fatty liver disease.
    Barb D; Portillo-Sanchez P; Cusi K
    Metabolism; 2016 Aug; 65(8):1183-95. PubMed ID: 27301803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of Xenopus GLP-1-Based Long-Acting Dual GLP-1/Y
    Yang Q; Tang W; Sun L; Yan Z; Tang C; Yuan Y; Zhou H; Zhou F; Zhou S; Wu Q; Song P; Fang T; Xu R; Han J; Jiang N
    J Med Chem; 2022 Oct; 65(20):14201-14220. PubMed ID: 36214844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease.
    Ishikawa T; Terai N; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Intern Med; 2024 Sep; 63(18):2491-2497. PubMed ID: 38346734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1.
    Yin YH; Sang LX; Chang B
    World J Gastroenterol; 2023 Dec; 29(48):6235-6238. PubMed ID: 38186863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Fang L; Li J; Zeng H; Liu J
    Prim Care Diabetes; 2024 Jun; 18(3):268-276. PubMed ID: 38555202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.
    Dhir G; Cusi K
    J Investig Med; 2018 Jan; 66(1):7-10. PubMed ID: 28918389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists.
    Zhang X; Cai Y; Yao Z; Chi H; Li Y; Shi J; Zhou Z; Sun L
    Peptides; 2023 Mar; 161():170948. PubMed ID: 36646385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.